These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report. Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352 [TBL] [Abstract][Full Text] [Related]
7. [Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis]. Funke-Chambour M; Geiser T Ther Umsch; 2016; 73(1):25-9. PubMed ID: 26884217 [TBL] [Abstract][Full Text] [Related]
8. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Moodley Y; Corte T; Richeldi L; King TE Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967 [TBL] [Abstract][Full Text] [Related]
9. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre. Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523 [TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Ogura T; Taniguchi H; Azuma A; Inoue Y; Kondoh Y; Hasegawa Y; Bando M; Abe S; Mochizuki Y; Chida K; Klüglich M; Fujimoto T; Okazaki K; Tadayasu Y; Sakamoto W; Sugiyama Y Eur Respir J; 2015 May; 45(5):1382-92. PubMed ID: 25504994 [TBL] [Abstract][Full Text] [Related]
11. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335 [TBL] [Abstract][Full Text] [Related]
12. The safety of new drug treatments for idiopathic pulmonary fibrosis. Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218 [TBL] [Abstract][Full Text] [Related]
13. Current approaches to the management of idiopathic pulmonary fibrosis. Raghu G; Richeldi L Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832 [TBL] [Abstract][Full Text] [Related]
14. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report. Hagmeyer L; Treml M; Priegnitz C; Randerath WJ Respiration; 2016; 91(4):327-32. PubMed ID: 27073887 [TBL] [Abstract][Full Text] [Related]
15. Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis. Perelas A; Glennie J; van Kerkhove K; Li M; Scheraga RG; Olman MA; Culver DA Pulm Pharmacol Ther; 2019 Dec; 59():101839. PubMed ID: 31518649 [TBL] [Abstract][Full Text] [Related]
16. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient? Hayton C; Chaudhuri N Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727 [TBL] [Abstract][Full Text] [Related]
17. A Patient with Idiopathic Pleuroparenchymal Fibroelastosis Showing a Sustained Pulmonary Function due to Treatment with Pirfenidone. Sato S; Hanibuchi M; Takahashi M; Fukuda Y; Morizumi S; Toyoda Y; Goto H; Nishioka Y Intern Med; 2016; 55(5):497-501. PubMed ID: 26935370 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750 [TBL] [Abstract][Full Text] [Related]
19. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. Sgalla G; Comes A; Richeldi L Expert Opin Drug Saf; 2021 Sep; 20(9):1035-1048. PubMed ID: 33881959 [TBL] [Abstract][Full Text] [Related]
20. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone. Varone F; Mastrobattista A; Franchi P; Viglietta L; Poletti V; Tomassetti S; Dubini A; Tagliaboschi L; Calandriello L; Farchione A; Larici AR Clin Respir J; 2018 Jan; 12(1):347-351. PubMed ID: 27322356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]